Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies

American Journal of Hematology

Volumn 92, Issue 12, 2017, Pages 1349-1355

  Origa, Raffaella ^a   Ponti, Maria Laura ^b   Filosa, Aldo ^c   Galeota Lanza, Alfonso ^c   Piga, Antonio ^d   Saracco, Giorgio Maria ^d   Pinto, Valeria ^e   Picciotto, Antonino ^f   Rigano, Paolo ^g   Madonia, Salvatore ^g   Rosso, Rosamaria ^h   D'Ascola, Domenico ⁱ   Cappellini, Maria Domenica ^j   D'Ambrosio, Roberta ^j   Tartaglione, Immacolata ^k   De Franceschi, Lucia ^l   Gianesin, Barbara ^e   Di Marco, Vito ^m   Forni, Gian Luca ^e  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b BROTZU HOSPITAL   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e GALLIERA HOSPITAL   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ Centro Microcitemia   (Italy)

^j UNIVERSITY OF MILAN   (Italy)

^k SECOND UNIVERSITY OF NAPLES   (Italy)

^l UNIVERSITY OF VERONA   (Italy)

^m UNIVERSITY OF PALERMO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; DIRECT ACTING ANTIVIRAL DRUG; FERRITIN; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; IRON CHELATING AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMOGLOBINOPATHY; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON OVERLOAD; ITALY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SICKLE CELL ANEMIA; VIRUS VIRULENCE; CHRONIC HEPATITIS C; COMPLICATION; LIVER CIRRHOSIS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEMOGLOBINOPATHIES; HEPATITIS C, CHRONIC; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85031681650     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24911     Document Type: Article

References (28)

1. Di Marco V, Capra M, Angelucci E, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood. 2010;116:2875–2883.
2. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521. 521 e511–516.
3. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
4. Rein DB, Wittenborn JS, Weinbaum CM, et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43:66–72.
5. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100:17–21.
6. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-thalassemia major in North America. Blood. 2004;104:34–39.
7. Di Marco V, Capra M, Gagliardotto F, et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica. 2008;93:1243–1246.
8. Perifanis V, Tziomalos K, Tsatra I, et al. Prevalence and severity of liver disease in patients with b thalassemia major. A single-institution fifteen-year experience. Haematologica. 2005;90:1136–1138.
9. Prati D, Maggioni M, Milani S, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica. 2004;89:1179–1186.
10. Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis. 2006;6:226–233.
11. Borgna-Pignatti C, Garani MC, Forni GL, et al. Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol. 2014;167:121–126.
12. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci. 2010;1202:1–9.
13. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153–194.
14. Harmatz P, Jonas MM, Kwiatkowski JL, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008;93:1247–1251.
15. Inati A, Taher A, Ghorra S, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol. 2005;130:644–646.
16. Kamal SM, Fouly AH, Mohamed MK, et al. Peginterferon alpha-2b therapy with and without ribavirin in patients with thalassemia: A randomized study. J Hepatol. 2006;44:S217.
17. Di Marco V, D'ambrosio R, Bronte F, et al. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication? Dig Liver Dis. 2016;48:650–655.
18. Vafiadis I, Trilianos P, Vlachogiannakos J, et al. Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit. Ann Hepatol. 2013;12:532–538.
19. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.
20. Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med. 2014;370:1560–1561.
21. Zachou K, Arvaniti P, Gatselis NK, et al. Patients with haemoglobinopathies and chronic Hepatitis C: a real difficult to treat population in 2016? Mediterr J Hematol Infect Dis. 2017;9:e2017003.
22. Hézode C, Colombo M, Bourliere M, et al. Elbasvir/grazoprevir for patients with Hepatitis C virus infection and inherited blood disorders: a phase III study. Hepatology. 2017;66:736–745.
23. Hussein NR. Sofosbuvir-containing regimen for the treatment of hepatitis C virus in a patient with sickle-thalassemia: The first case report. Int J Infect. 2017;4:e38077.
24. Papadopoulos N, Deutsch M, Georgalas A, et al. Simeprevir and sofosbuvir combination treatment in a patient with HCV cirrhosis and HbS Beta 0-thalassemia: efficacy and safety despite baseline hyperbilirubinemia. Case Rep Hematol. 2016;2016:7635128.
25. Agenzia Italiana del Farmaco. AIFA: aggiornato algoritmo per scelta terapia epatite C cronica in collaborazione con AISF. 2015. Available from: http://www.aifa.gov.it/content/aifa-aggiornato-algoritmo-scelta-terapia-epatite-c-cronica-collaborazione-con-aisf. Accessed March 20, 2017.
26. University of Liverpool. HEP Drug Interaction Checker. 2017. Available from: http://www.hep-druginteractions.org/. Accessed March 20, 2017.
27. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179.
28. R Core Team. R: A language and environment for statistical computing. 2016. Available from: https://www.R-project.org/. Accessed 20 March, 2017.